1文献来源Zhang Q,Luo J,Wu S,et al.Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade[J].Cancer Discov,2020,10(12):1842-1853.2证据水平2b...1文献来源Zhang Q,Luo J,Wu S,et al.Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade[J].Cancer Discov,2020,10(12):1842-1853.2证据水平2b。3背景用于监测免疫检查点抑制剂治疗反应的生物标志物很少,尤其是可用于多种癌症类型的生物标志物。展开更多
1文献来源Vansteenkiste JF,Cho BC,Vanakesa T,et al.Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer(MAGRIT):A randomised,double-...1文献来源Vansteenkiste JF,Cho BC,Vanakesa T,et al.Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer(MAGRIT):A randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet Oncol,2016,17(6):822-835.2证据水平1b。3背景?在完全切除的非小细胞肺癌(non-small cell lung cancer,NSCLC)患者中,只有不到一半的患者被治愈,而其他患者的癌症复发通常是致命的。在过去的几十年里,已研究了几种辅助治疗方法来改善这些患者的预后。?目前发现MAGE-A3是肿瘤组织表达最多的肿瘤-睾丸抗原(cancer-testis antigen,CTA)之一,被认为是真正的肿瘤特异性抗原,在许多肿瘤中表达,例如恶性黑色素瘤、肺癌、头颈部肿瘤、肝细胞癌等。30%~50%的NSCLC存在MAGE-A3表达,其中鳞癌(48%)比非鳞癌(24%)比例更高。而对于可切除的NSCLC,只有不到一半的患者达到临床治愈,更多的患者会出现肿瘤复发。传统的辅助化疗无法提供更多的临床获益,针对MAGE-A3抗原的肺癌疫苗对术后患者体内残存的癌细胞可能具有一定的治疗潜力。展开更多
1文献来源Rudin CM,Awad MM,Navarro A,et al.Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer:Randomized,double-blind,phaseⅢKEYNOTE-604 study[J].J Cli...1文献来源Rudin CM,Awad MM,Navarro A,et al.Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer:Randomized,double-blind,phaseⅢKEYNOTE-604 study[J].J Clin Oncol,2020,38(21):2369-2379.2证据水平1b。3背景依托泊苷联合铂类是广泛期小细胞肺癌(extensive-stage small-cell lung cancer,ES-SCLC)一线标准治疗方案之一。帕博丽珠单抗单药在小细胞肺癌中显示出抗肿瘤活性。展开更多
1文献来源Yang JJ,Zhou CC,Huang YS,et al.Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases(BRAIN):A multicentre,phase 3,open-label,parallel,ra...1文献来源Yang JJ,Zhou CC,Huang YS,et al.Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases(BRAIN):A multicentre,phase 3,open-label,parallel,randomised controlled trial[J].Lancet Respir Med,2017,5(9):707-716.2证据水平1b。3背景-目前全脑放疗(whole-brain radiation therapy,WBRT)仍是非小细胞肺癌(non-small cell lung cancer,NSCLC)多发性脑转移的标准治疗方式,而对于EGFR突变的患者,第一代和第二代TKI不仅显著提高了无进展生存期,而且对脑转移有一定的疗效。展开更多
1文献来源Le D T,Kim T W,Van Cutsem E,et al.PhaseⅡopen⁃label study of pembrolizumab in treatment⁃refractory,microsatellite instability⁃high/mismatch repair⁃deficient metastatic colorectal cancer:KEYNOTE⁃164[J].J Clin ...1文献来源Le D T,Kim T W,Van Cutsem E,et al.PhaseⅡopen⁃label study of pembrolizumab in treatment⁃refractory,microsatellite instability⁃high/mismatch repair⁃deficient metastatic colorectal cancer:KEYNOTE⁃164[J].J Clin Oncol,2019,38(1):11-19.2证据水平2a。3背景•微卫星高度不稳定性(microsatellite instability high,MSI⁃H)或错配修复功能缺陷(mismatch repair⁃deficient,dMMR)结直肠癌患者的预后比微卫星稳定(microsatellite stability,MSS)结直肠癌患者的预后差。展开更多
1文献来源Deng Y,Chi P,Lan P,et al.Modified FOLFOX6 with or without radiation versus Fluorouracil and Leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer:Initial results of the Chinese ...1文献来源Deng Y,Chi P,Lan P,et al.Modified FOLFOX6 with or without radiation versus Fluorouracil and Leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer:Initial results of the Chinese FOWARC multicenter,open-label,randomized three-arm phaseⅢtrial[J].J Clin Oncol,2016,34(27):3300-3307.2证据水平1b。3背景术前给予5-氟尿嘧啶(Fluorouracil,FU)为基础的新辅助化疗+全直肠系膜切除术(total mesorectal excision,TME)+以5-FU为基础的术后辅助化疗+术后放疗是目前局部进展期直肠癌的标准治疗方法。在多个国际大型临床研究中,仅有CAO/ARO/AIO-04研究证实5-FU联合奥沙利铂作为围手术期化疗可将3年无病生存率(disease-free survival,DFS)从71.2%提高至75.9%。展开更多
1文献来源Pezzi TA,Mohamed ASR,Fuller CD,et al.Radiation therapy is independently associated with worse survival after R0-resection for stageⅠ~Ⅱnon-small cell lung cancer:An analysis of the National Cancer Data Base[...1文献来源Pezzi TA,Mohamed ASR,Fuller CD,et al.Radiation therapy is independently associated with worse survival after R0-resection for stageⅠ~Ⅱnon-small cell lung cancer:An analysis of the National Cancer Data Base[J].Ann Surg Oncol,2017,24(5):1419-1427.2证据水平2a。3背景1998年发表的一篇针对肺癌术后放射治疗的荟萃分析显示,Ⅰ~Ⅱ期手术切除的非小细胞肺癌(non-small cell lung cancer,NSCLC)患者接受术后放射治疗(postoperative radiotherapy,PORT)与更差的生存预后相关,但考虑与当时落后的放疗仪器及技术也有一定关系。已有利用美国国家癌症数据库(National Cancer Data Base,NCDB)的真实世界研究发现pN2的NSCLC患者行PORT能够获得生存获益,因此,本文旨在运用该数据库分析早期(Ⅰ~Ⅱ期)NSCLC行PORT获益情况。随着放疗仪器及技术改进后,R0切除的Ⅰ~Ⅱ期NSCLC行PORT与预后关系尚未可知。展开更多
文摘1文献来源Zhang Q,Luo J,Wu S,et al.Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade[J].Cancer Discov,2020,10(12):1842-1853.2证据水平2b。3背景用于监测免疫检查点抑制剂治疗反应的生物标志物很少,尤其是可用于多种癌症类型的生物标志物。
文摘1文献来源Vansteenkiste JF,Cho BC,Vanakesa T,et al.Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer(MAGRIT):A randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet Oncol,2016,17(6):822-835.2证据水平1b。3背景?在完全切除的非小细胞肺癌(non-small cell lung cancer,NSCLC)患者中,只有不到一半的患者被治愈,而其他患者的癌症复发通常是致命的。在过去的几十年里,已研究了几种辅助治疗方法来改善这些患者的预后。?目前发现MAGE-A3是肿瘤组织表达最多的肿瘤-睾丸抗原(cancer-testis antigen,CTA)之一,被认为是真正的肿瘤特异性抗原,在许多肿瘤中表达,例如恶性黑色素瘤、肺癌、头颈部肿瘤、肝细胞癌等。30%~50%的NSCLC存在MAGE-A3表达,其中鳞癌(48%)比非鳞癌(24%)比例更高。而对于可切除的NSCLC,只有不到一半的患者达到临床治愈,更多的患者会出现肿瘤复发。传统的辅助化疗无法提供更多的临床获益,针对MAGE-A3抗原的肺癌疫苗对术后患者体内残存的癌细胞可能具有一定的治疗潜力。
文摘1文献来源Rudin CM,Awad MM,Navarro A,et al.Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer:Randomized,double-blind,phaseⅢKEYNOTE-604 study[J].J Clin Oncol,2020,38(21):2369-2379.2证据水平1b。3背景依托泊苷联合铂类是广泛期小细胞肺癌(extensive-stage small-cell lung cancer,ES-SCLC)一线标准治疗方案之一。帕博丽珠单抗单药在小细胞肺癌中显示出抗肿瘤活性。
文摘1文献来源Le D T,Kim T W,Van Cutsem E,et al.PhaseⅡopen⁃label study of pembrolizumab in treatment⁃refractory,microsatellite instability⁃high/mismatch repair⁃deficient metastatic colorectal cancer:KEYNOTE⁃164[J].J Clin Oncol,2019,38(1):11-19.2证据水平2a。3背景•微卫星高度不稳定性(microsatellite instability high,MSI⁃H)或错配修复功能缺陷(mismatch repair⁃deficient,dMMR)结直肠癌患者的预后比微卫星稳定(microsatellite stability,MSS)结直肠癌患者的预后差。
文摘1文献来源Deng Y,Chi P,Lan P,et al.Modified FOLFOX6 with or without radiation versus Fluorouracil and Leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer:Initial results of the Chinese FOWARC multicenter,open-label,randomized three-arm phaseⅢtrial[J].J Clin Oncol,2016,34(27):3300-3307.2证据水平1b。3背景术前给予5-氟尿嘧啶(Fluorouracil,FU)为基础的新辅助化疗+全直肠系膜切除术(total mesorectal excision,TME)+以5-FU为基础的术后辅助化疗+术后放疗是目前局部进展期直肠癌的标准治疗方法。在多个国际大型临床研究中,仅有CAO/ARO/AIO-04研究证实5-FU联合奥沙利铂作为围手术期化疗可将3年无病生存率(disease-free survival,DFS)从71.2%提高至75.9%。
文摘1文献来源Pezzi TA,Mohamed ASR,Fuller CD,et al.Radiation therapy is independently associated with worse survival after R0-resection for stageⅠ~Ⅱnon-small cell lung cancer:An analysis of the National Cancer Data Base[J].Ann Surg Oncol,2017,24(5):1419-1427.2证据水平2a。3背景1998年发表的一篇针对肺癌术后放射治疗的荟萃分析显示,Ⅰ~Ⅱ期手术切除的非小细胞肺癌(non-small cell lung cancer,NSCLC)患者接受术后放射治疗(postoperative radiotherapy,PORT)与更差的生存预后相关,但考虑与当时落后的放疗仪器及技术也有一定关系。已有利用美国国家癌症数据库(National Cancer Data Base,NCDB)的真实世界研究发现pN2的NSCLC患者行PORT能够获得生存获益,因此,本文旨在运用该数据库分析早期(Ⅰ~Ⅱ期)NSCLC行PORT获益情况。随着放疗仪器及技术改进后,R0切除的Ⅰ~Ⅱ期NSCLC行PORT与预后关系尚未可知。
